Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome

Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02045654

Enrollment

Registered

2014-01-27

Start date

2014-01-31

Completion date

2015-03-31

Last updated

2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic Syndrome

Brief summary

To assess the efficacy of decitabine and identify predictors for response to decitabine therapy.

Detailed description

* Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications * Survival and response Analysis * Response rate * Overall survival * Leukemia free survival

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed Myelodysplastic syndrome Diagnosed with MDS (de novo or secondary) based on the World Health Organization (WHO) classifications

Design outcomes

Primary

Measure	Time frame	Description
Response rate	1 year	International Working Group (IWG) response criteria

Secondary

Measure	Time frame	Description
Overall survival	1 year	measured from the date of decitabine therapy to the date of death or the last follow-up visit
Leukemia free survival	1 year	the date of decitabine therapy to the date of death or leukemic transformation

Countries

South Korea

Contacts

Primary ContactJun Ho Jang, Pf

jh21.jang@samsung.com

Outcome results